We examined 100 symptomatic Gulf War veterans (patients) and 100 controls for immunologic assays. The veterans and controls were compared for the percentage of T cells (CD3); B cells (CD19); helper:suppressor (CD4:CD8) ratio; natural killer (NK) cell activity; mitogenic response to phytohemagglutinin (PHA) and pokeweed mitogen (PWM); level of immune complexes; myelin basic protein (MBP) and striated and smooth muscle autoantibodies; and antibodies against Epstein-Barr virus, cytomegalovirus, herpes simplex virus type 1 (HSV-1), HSV-2, human herpes Type 6 (HHV-6), and Varicella zoster virus (VZV). The percentage of T cells in patients versus controls was not significantly different, whereas a significantly higher proportion of patients had elevated T cells compared with controls. The percentage of B cells was significantly elevated in the patients versus the controls. The NK cell (NK) activity was significantly decreased in the patients (24.8 ± 16.5 lytic units) versus the controls (37.3 ± 26.4 lytic units). The percentage of patients with lower than normal response to PHA and PWM was significantly different from controls. Immune complexes were significantly increased in the patients (53.1 ± 18.6, mean ± SD) versus controls (34.6 ± 14.3). Autoantibody titers directed against MBP and striated or smooth muscle were significantly greater in patients versus controls. Finally, the patients had significantly greater titers of antibodies to the viruses compared with the controls (p < 0.001). These immune alterations were detected 2–8 years after participation in the Gulf War. The immune alterations are consistent with exposure to different environmental factors. We conclude that Gulf War syndrome is a multifaceted illness with immune function alterations that may be induced by various factors and are probably associated with chronic fatigue syndrome.

Key words: autoantibodies, B cell, Gulf War syndrome, immune complexes, natural killer cell, T cell. Environ Health Perspect 112:840–846 (2004). doi:10.1289/ehp.6881 available via http://dx.doi.org/ (Online 17 February 2004)
cytokine (TSH); and basic immunology [antinuclear antibody (ANA), rheumatoid factor (RF), and total IgA, IgG, and IgM].

Lymphocyte subset enumeration. Direct immunofluorescence staining of cell surface antigen was accomplished using the Becton-Dickinson FACSCan Immunocytometry system (San Jose, CA). The peripheral mononuclear cells are treated with monoclonal antibodies conjugated to fluorescein isothiocyanate (FITC) or phycoerythrin (PE). The blood samples were first treated with red blood cell lysing solution. Cells were then washed, stained with monoclonal antibody, and then analyzed with the FACSCan flow cytometer. We used the following pairs of FITC- or PE-conjugated monoclonal antibodies: CD45/CD14 for T-helper cells, CD3/CD8 for suppressor cells, CD3/CD19 for T and B cells, and CD3/CD16 plus CD56 for natural killer (NK) cells (NKHT3+ and NKHT3–). Using these sets of monoclonal antibodies, we determined the percentage of positively stained cells for each marker pair and the percentage of double stained cells.

Preparation of peripheral blood leukocytes. Leukocytes were prepared from heparinized peripheral venous blood by Ficol-Hypaque density gradient (Sigma Chemical Company, St. Louis, MO). Cells were washed three times with Hanks balanced salt solution and resuspended to a concentration of 107 cells/mL in a complete medium (CM) that consisted of RPMI-1640 supplemented with 10% fetal calf serum and 1% antibiotics (100 U penicillin and 100 µg/mL streptomycin). We examined purity of the cells by flow cytometry using CD45/CD14 monoclonal antibodies; purity was >95%. Cells were used for different functional assays within 1 hr of isolation.

NK cell cytotoxicity assay. We used a standard 4-hr 51Cr-release assay (Whiteside et al. 1990) to determine NK cell cytotoxicity. Briefly, we added 1 x 104 51Cr-labeled K562 tumor target cells in 0.1 mL CM to different wells of a microtiter plate. Effector cells were then pipetted into triplicate wells for each dilution to give effector:target ratios of 6:1, 12:1, 24:1, and 48:1. After a 4-hr incubation at 37°C, the plates were centrifuged at 1,400 rpm for 4 min, and 0.1 mL of supernatant was collected from each well and placed in a gamma counter. The percentages of isotope released were calculated using the following formula:

\[
\text{Percentage of lysis} = \frac{\text{Experimental release} - \text{Spontaneous release}}{\text{Total release} - \text{Spontaneous release}} \times 100
\]

The results of NK cell assay for each effector:target ratio was expressed in terms of lytic units (LU), calculated as described by Whiteside et al. (1990).

Lymphocyte mitogenic assay. Lymphocytes were isolated and tested for mitogenic activity as described by Fletcher et al. (1992) and Maino et al. (1995). Briefly, 5 x 104 lymphocytes per 0.1 mL CM were cultured in flat-bottom microtiter plate wells. Cells from patients and controls, as well as cells with known mitogenic stimulation, were cultured with or without an optimal concentration of either phytohemagglutinin (PHA; 25 µg/mL; Grand Island Biological Company, Grand Island, NY) or pokeweed mitogen (PWM; 5 µg/mL; Sigma Chemical Company). After 48 hr of incubation, the cells were harvested and stained with CD69 monoclonal antibody conjugated to fluorescent dye and analyzed by flow cytometry. Wells with no mitogens added (negative control) provided information about the media and cells used in the assay so we could determine possible nonspecific modulatory activity. Values for patients and controls were compared with the daily negative and positive control for each assay. Results were calculated using the following formula:

\[
\text{Percentage of stimulation} = \frac{\text{Activated sample} - \text{Unstimulated sample}}{\text{Activated control} - \text{Unstimulated control}} \times 100
\]

We estimated three stimulation levels: low, < 75% of the number of control cells; normal, 75–125% of the number of control cells; and elevated, > 125% of the number of control cells.

Myelin basic protein antibody. The antibody to human myelin basic protein (MBP) was analyzed as previously described (Vojdani et al. 1992). Briefly, MBP (Sigma Chemical Co.) was checked for purity by polyacrylamide gel electrophoresis (Diebler et al. 1972). Antisera to MBP were induced in rabbits by repeated injection of the protein in complete Freund’s adjuvant. Antibody activity in the rabbit sera and the patient and control samples was detected by adding different dilutions (1:100–1:10,000) of sera to wells of a microtiter plate previously coated with MBP. MBP (250 µg/mL) was dissolved in carbonate buffer (pH 9.6), and 200 µL of this solution was added to each well. After incubation, washing, and blocking with 1.5% bovine serum albumin plus gelatin, 200 µL of either diluted rabbit or human serum was added to the wells. Incubation was repeated for 1 hr at 25°C, and the sera were shaken out of the wells, which were then washed five times with wash solution. Next, 200 µL peroxidase-conjugated goat anti-rabbit or goat anti-human IgM (optimal dilution) was added to the appropriate well. After incubation and repeated washing, 200 µL substrate was added to each well. Plates were incubated for 1 hr at room temperature and read in a microtiter reader at 480 nm wavelength. We plotted a titration curve using rabbit antisera, and compared patient and control sera with this standard curve. Results are expressed by the ELISA (enzyme-linked immunosorbent assay) values.

Striated and smooth muscle antibody assay. We purchased skeletal muscle myoblast cell line CRL-1769 and smooth muscle cell line ATCC CRL-1444 from American Type Culture Collection (Rockville, MD). Cells were grown in Dulbecco’s modified Eagle’s medium (90%) and fetal bovine serum (10%). After 7 days in culture, the cells were harvested, sonicated, and used for coating ELISA plates. Each ELISA microplate well was coated with 100 µL cell lysate containing 10 µg protein in 0.1 M carbonate buffer (pH 9.5). Plates were incubated overnight at 4°C and then washed three times with 200 µL Tris-buffered saline containing 0.05% Tween 20 (pH 7.4). With the exception of goat anti-human IgG F(ab')2, all other steps were similar to the MBP ELISA method described above. To detect nonspecific binding, we used all reagents except human serum in several control wells and coated some wells with different tissue antigens.

Immune complexes. We measured IgG, IgM, and IgA immune complexes by coating microtiter plates with anti-C1q. Addition of serum, second antibody, and substrate was similar to procedures for measuring MBP antibody by ELISA.

Antibodies to viruses. Antibody titers against Epstein-Barr virus (EBV); cytomegalovirus (CMV); herpes simplex virus type 1 (HSV-1), HSV-2, HHV-6; and Varicella zoster virus (VZV) were measured by ELISA using kits from Diamedix (Miami, FL).

Determination of expected ranges. We obtained expected ranges as follows:

- Earlier publications.
- Suppliers of the CD markers (Becton-Dickinson) carried out in-house verification using blood from 100 healthy controls from which the means, SDs, and 95% confidence intervals (CIs) were determined (Babcock et al. 1987, Shearer et al. 2003).
- The manufacturers of the immune complex and viral antibody test kits provided an expected range with their products (Abbas et al. 1994, Christenson et al. 1992, Matheson et al. 1990, Shehab and Brunell 1983).
- We obtained expected ranges for NK cell activity from Whiteside et al. (1990) and confirmed them in our laboratory by performing the assay on 500 specimens from healthy subjects.
- We determined expected ranges for PHA and PWM mitogenesis and for autoantibodies to MBP and striated and smooth muscle in-house using 100 healthy controls for which means, SDs, and 95% CIs were calculated.
Thus, the expected ranges are a combination of suppliers’ recommendations and in-house quality control.

**Statistics.** We used two-sided critical t-tests for comparison of independent means and Z-tests for comparison of independent proportions as described by Bourke et al. (1985).

### Results

**Basic laboratory tests.** We observed some variations from expected normal ranges in both controls and patients, respectively, as follows: CBC, 21 and 27%; blood glucose, 12 and 9%; lipid profile, 18 and 22%; liver enzymes, 14 and 19%; T3, T4, and TSH, 9 and 12%; ANA, 7 and 11%; RF, 10 and 14%; and immunoglobulins, 6 and 8%. Z-tests for independent proportions revealed no significant difference between controls and patients for each test.

**Comparison of patients (groups A and B) and controls (groups C and D).** We analyzed the data to determine if differences existed between patient groups A and B and their controls for each tested immune parameter (data not shown). No significant differences were found; therefore, we combined patient groups A and B and control groups C and D for further statistical analysis. In addition, we observed no differences between males and females in any of the groups.

**CD3 T cells.** The percentages of CD3 T cells present in the peripheral blood of controls versus patients are presented in Table 1. The mean percentage of CD3 cells in patients (72.8 ± 10.3%, mean ± SD) was slightly higher compared with the controls (71.6 ± 7.3%), but the difference was not significant. However, the percentage of individuals that fell outside of the expected range of 53–79% CD3 cells was different between the two groups: 2% of controls and 9% of patients had < 53% CD3 cells, and 5% of controls and 30% of patients had > 79%. The critical Z- and p-values for variance from normal distribution were significant (p < 0.05).

**CD19 B cells.** The percentages of CD19 B cells present in the peripheral blood of controls versus patients are presented in Table 1. The mean percentage of CD19 cells in patients (11.5 ± 3.1%, mean ± SD) was higher compared with the controls (10.0 ± 1.9%), but the difference was not significant. The critical Z- and p-values for variance from normal distribution were significant (p < 0.05).

**CD4:CD8 ratio.** The CD4:CD8 (helper:suppressor) ratios for controls and patients are listed in Table 1. The ratio was significantly (p < 0.001) elevated in patients (2.23 ± 0.87, mean ± SD) compared with controls (1.74 ± 0.34). The Z-values for the percentage of patients with values outside the expected distribution of the CD4:CD8 ratio were significantly different compared with those of the controls (p < 0.0001).

**NK cell activity.** The data obtained for NK lytic activity are presented in Table 2. The lytic activity was significantly less (p < 0.001) in patients (24.8 ± 16.5%) than in controls (37.3 ± 26.4%). The percentages of individuals with > 50 LU were not different between the two groups (p = not significant), whereas the p-value for the percentage of patients with < 20 LU was significant (p < 0.01).

**Mitogen stimulation.** The results of PHA and PWM stimulation of peripheral lymphocytes in the controls and patients are summarized in Table 2. The mean percentage of stimulation by either PHA or PWM was not different between controls and patients. However, the distribution of stimulation values did differ between the two groups. For PHA, more GWS patients (32%) had a stimulation index > 125% compared with the controls (15.9 ± 11.4). For PWM, more GWS patients (32%) had a stimulation index > 125% compared with the controls (15.9 ± 11.4).

**Autoantibodies.** The observations for IgM anti-MBP in the controls and patients are shown in Table 3. The mean ELISA units for IgM antibodies were significantly (p < 0.001) greater in patients (45.9 ± 35.8) than in controls (28.4 ± 13). The Z-value for the percentage of patients with > 50 ELISA units was significant (p < 0.0001). The mean value for the patients with IgM titers > 50 ELISA units was 75.7 ± 15.9.

**Antibodies to muscle (striated and smooth).** The results for IgG antibodies to both smooth and striated muscle are shown in Table 3. The mean IgG titers observed in the patients (42.8 ± 72.3) were significantly (p < 0.0001) greater than those for the controls (15.9 ± 11.4).

**Immune complexes.** The observations on immune complexes found in the peripheral blood of controls and patients are summarized in Table 3. The mean ELISA units for immune complexes were significantly (p < 0.0001) greater in patients (14.9 ± 14.9) than in controls (3.8 ± 3.8). The Z-value for the percentage of patients with > 50 ELISA units was significant (p < 0.0001). The mean value for the patients with immune complexes > 50 ELISA units was 75.7 ± 15.9.

### Table 1. Percentage of CD3 T cells and CD19 B cells and CD4:CD8 ratios in controls and patients.

| Cell type or ratio | Percent (mean ± SD) | Expected range (%) | Percent of subjects outside the expected range | Below bottom of range | Above top of range |
|--------------------|---------------------|--------------------|-----------------------------------------------|-----------------------|-------------------|
| CD3 T cells        |                     |                    |                                               |                       |                   |
| Controls           | 71.6 ± 7.3          | 53–79              | 2                                             | 5                     |                   |
| Patients           | 72.8 ± 10.3         | 53–79              | 9                                             | 30                    |                   |
| CD19 B cells       |                     |                    |                                               |                       |                   |
| Controls           | 11.5 ± 3.1          | 5–15               | 0                                             | 5                     |                   |
| Patients           | 16.1 ± 6.0          | 5–15               | 4                                             | 49                    |                   |
| CD4:CD8 ratio      |                     |                    |                                               |                       |                   |
| Controls           | 1.74 ± 0.34         | 1.0–2.5            | 0                                             | 3                     |                   |
| Patients           | 2.23 ± 0.87         | 1.0–2.5            | 4                                             | 32                    |                   |

Controls and patients were compared using Student’s t-test. Critical Z-values were obtained for the normal distribution.

### Table 2. NK cell activity and lymphocyte stimulation with PHA and PWM in controls and patients.

| Cell type | Lytic units (LU) | Expected range (%) | Percent of subjects outside the expected range | Below bottom of range | Above top of range |
|-----------|------------------|--------------------|-----------------------------------------------|-----------------------|-------------------|
| NK cell activity |                     |                    |                                               |                       |                   |
| Controls   | 37.3 ± 26.4      | 20–50              | 8                                             | 9                     |                   |
| Patients   | 24.8 ± 16.5      | 20–50              | 48                                            | 4                     |                   |
| PHA        |                   |                    |                                               |                       |                   |
| Controls   | 84.9 ± 20.2      | 75–125             | 6                                             | 0                     |                   |
| Patients   | 84.4 ± 19.9      | 75–125             | 32                                            | 4                     |                   |
| PWM        |                   |                    |                                               |                       |                   |
| Controls   | 85.4 ± 11.5      | 75–125             | 7                                             | 1                     |                   |
| Patients   | 87.3 ± 18.6      | 75–125             | 23                                            | 1                     |                   |

Controls and patients were compared using Student’s t-test and Z-test. NS, not significant.
in Figure 1. Immune complexes were significantly (p < 0.001) elevated in the patients (52.1 ± 18.5 mEq/mL) compared with controls (34.5 ± 14.3 mEq/mL) (Figure 1A). In addition, the percentage of patients with immune complexes > 50 mEq/mL was significantly higher than that for controls (p < 0.01) (Figure 1B).

Antibodies to viruses. The results obtained on antibodies to viruses are presented in Table 4. Mean titer levels for each virus were significantly (p < 0.001) higher in the patients than in controls.

The differences in the mean titer levels between the patients and controls resulted from a disproportionate number (percentage) of patients who had elevated titers to each virus. For example, the mean IgM antibodies to EBV viral capsid antigen (VCA) was significantly higher in patients than controls (34.5 ± 18.5 mEq/mL) compared with controls (34.5 ± 18.5 mEq/mL) (Figure 1A). In addition, the percentage of patients with elevated titers to each virus. For example, the mean IgM antibodies to EBV viral capsid antigen (VCA) was significantly higher in patients than controls (34.5 ± 18.5 mEq/mL) compared with controls (34.5 ± 18.5 mEq/mL) (Figure 1A).

Table 3. IgM antibody against MBP and IgG antibodies against smooth and striated muscle in controls and patients.

| Antibody type | Level of IgM antibody | Expected range (ELISA units) | Percent of subjects above top of range |
|---------------|------------------------|-------------------------------|---------------------------------------|
| Anti-MBP      |                        |                               |                                       |
| Controls      | 28.4 ± 13              | 0–50                          | 0                                     |
| Patients      | 45.9 ± 35.8            | 0–50                          | 34                                    |
| Against smooth and striated muscle | | | | |
| Controls      | 15.9 ± 11.4            | 0–20                          | 9                                     |
| Patients      | 42.8 ± 72.3            | 0–20                          | 37                                    |

The most critical but open question in immunosurveillance is whether information on differences between individuals with abnormal NK, T- and B-cell function can predict future development of cancer or autoimmune diseases. Indications of the significant role for NK cells in preventing the development of cancer in both mice and humans have been reported (Imai et al. 2000; Wilson et al. 2001). A prospective cohort study among a Japanese general population showed that medium and high cytotoxic activities were associated with reduced cancer risk, whereas low activity was associated with an increased risk (Imai et al. 2000). Wilson et al. (2001)

![Figure 1. Total level of immune complexes (A) and percentage of elevation (B) in controls and patients with GWS. Error bars indicate SD. Controls and patients were compared using Student’s t-test. Critical Z-values were also obtained for normal distribution; p = 0.01, Z = 5.58, t-test = 7.46.](image-url)
demonstrated suppressed NK cell activity with altered host resistance in mice. NK cell activity was incrementally decreased by intravenous administration of antibody to NK surface receptors. After a ≥ 80% decrease in spontaneous NK activity, a challenge with ≥ 1 x 10³ B16F10 melanoma cells resulted in increased tumor burden in the lungs (Wilson et al. 2001). Furthermore, when challenged with 1 x 10³ melanoma cells, tumor burden was not increased until spontaneous NK activity had been decreased by ≤ 50–60%. Altered host resistance is a function of both the magnitude of the decrease in NK activity and the magnitude of the challenge to the host (Wilson et al. 2001).

Increased levels of autoantibodies to various organs in humans, including MBPs, have been reported after exposure to toxic chemicals (McConnachie and Zahalsky 1991, 1992; Thrasher et al. 1987, 1990, 1993; Vojdani et al. 1992, 1993). Thus, the increased incidence of antibodies to MBP and striated and smooth muscle (Table 3) in the GWS patients is suggestive of autoimmunity, possibly resulting in tissue injury from toxic chemical exposure (Cooper et al. 2002; Griem et al. 1998). The presence of IgM antibodies to MBP appears to indicate that an active process involving release of these self-antigens is occurring up to 8 years after injury. Central nervous system injury has been reported in research animals exposed to pyridostigmine bromide, DEET (N,N-diethyl-m-toluamide), and permethrin (Abou-Donia et al. 2001) and in some GWS patients, in particular, ALS (Haley 2003; Horner et al. 2003). The observations presented here suggest that additional studies are needed on neural damage and/or axonal demyelination in symptomatic Gulf War veterans. Neural antigen and MBP antibodies have been reported in patients with neurologic disorders (Terryberry et al. 1998; Willison and Yuki 2002), including ALS (Rogers et al. 1992, 1993). Thus, it would appear from these observations on increased immune complexes in the patient population in the present study that inflammation and autoimmune reactions may exist in a subgroup of patients with GWS. Circulating immune complexes containing IgG, IgM, and IgA antibodies can generate a variety of substances associated with muscle damage and the acute phase response, activating the classic pathway of complements (Sorensen et al. 2003).

Finally, we tested the GWS patients to determine if an increase in antibodies to several HSV types was present (Table 4, Figure 2). The data clearly show that significantly increased

---

### Table 4. Titer levels of antibodies to viruses found in controls and patients (expressed in ELISA units).

| Virus    | Controls (mean ± SD) | Patients (mean ± SD) | Expected range | T-Test range | p-Value |
|----------|----------------------|----------------------|----------------|--------------|--------|
| EBV VCA IgM | 197 ± 166           | 384 ± 400            | 0–300          | 6.627        | < 0.001|
| CMV IgG    | 143 ± 121            | 271 ± 277            | 0–200          | 4.234        | < 0.001|
| HSV-1 IgG  | 197 ± 173            | 491 ± 469            | 0–400          | 5.881        | < 0.001|
| HSV-2 IgG  | 144 ± 162            | 343 ± 305            | 0–400          | 5.473        | < 0.001|
| HHV-6 IgG  | 14.9 ± 8.7           | 42.6 ± 54.8          | 0–20           | 5.010        | < 0.001|
| VZV IgG    | 15.4 ± 11.4          | 90.5 ± 149           | 0–20           | 4.391        | < 0.001|

VCA, viral capsid antigen. Controls and patients were compared using Student’s t-test.

---

![Figure 2](image-url)  
**Figure 2.** Percent elevation above the expected range of viral antibodies in controls and patients with GWS. p < 0.01.

---

![Figure 3](image-url)  
**Figure 3.** Hypothetical description of GWS in relation to environmental factors present in the Gulf War and their effects on individuals with no genetic susceptibility to chemicals versus those with genetic polymorphism and susceptibility to chemicals resulting in immune function abnormalities and possibly immune dysregulation. Only in the subpopulation susceptible to these environmental factors may these immune abnormalities result in viral reactivation and symptoms similar to those of chronic fatigue and fibromyalgia. PAH, polycyclic aromatic hydrocarbons.
antibody titers occurred in the GWS patients compared with the controls for each virus tested (EBV, CMV, HSV-1, HSV-2, HHV-6, and VZV; Table 4). When the limitations were limited to only affected individuals, the increased titers to each virus was even more evident (Figure 2). Exactly when the viral infections occurred cannot be determined from these data. However, the increased IgM antibodies to EBV VCA suggest that reactivation of EBV is probably occurring and may involve the other viruses. To our knowledge, there has been no other report regarding increased viral antibodies in GWS patients. In addition, infections with *Mycoplasma fermentans*, *Mycoplasma hominis*, and *Mycoplasma penetrans* must also be considered (Vojdani and Franco 1999). Although we did not perform polymerase chain reaction to detect DNA of these viruses, the presence of viral antibodies and mycoplasma DNA may be related to dysregulation of the immune system found in this study.

## Conclusion

The observations in these GWS patients suggest that an alteration in the number and function of T and B cells and NK cell activity has occurred that may be associated with service in the Persian Gulf. Furthermore, the presence of antibodies to MBP and striated muscle, increased immune complex, and increased antibody titers to several DNA viruses indicate that viral reactivation and/or an active inflammatory immune process may be ongoing in some GWS patients (Ferguson and Cassaday 2001/2001; Patarca 2001; Rook and Zumia 1997).

Based on these observations and earlier reports by others, we believe that GWS is a multifactorial disease caused by exposure to a variety of environmental conditions, for example, xenobiotics, vaccinations, and other stressor-related conditions of the Gulf War environment as summarized in Figure 3. We believe that the outlined multiple factors along with genetic susceptibility due to polymorphism of PON1, loss of neuropathy target esterase, glutathione S-transferase, cytochrome P450 enzymes, or other factors may affect some individuals, resulting in immune dysregulation (Haley et al. 1999; Loewenstein-Lichtenstein et al. 1995; Shields 1994; Whatt et al. 2000). These immune functional alterations reported herein may cause viral reactivation and induction of proinflammatory cytokines, resulting in symptoms similar to those of chronic fatigue and fibromyalgia, as well as other symptoms of GWS (Ferguson and Cassaday, 2001/2002; Patarca 2001; Rook and Zumia 1997; Zhang et al. 1999). The variation in individual susceptibility to environmental stresses and toxicants is a new discipline (toxicogenomics), initiated at the National Institute of Environmental Health Sciences, that studies the relationship between genes and environmental stressors (Waters et al. 2003). This new knowledge of toxicogenomics may enable us to answer why, upon exposure to these environmental factors, some soldiers developed GWS and others did not. Finally, it appears that additional studies involving asymptomatic deployed Gulf War veterans versus symptomatic Gulf War veterans would be beneficial in further understanding the immunologic observations presented herein.

## References

Abbas AK, Lichtman AH, Pober JS. 1994. Cellular and Molecular Immunology. 2nd ed. Philadelphia:W.B. Saunders and Company, 393.

Abou-Donia MB, Goldberg LB, Jones KH, Abdel-Rahman AA, Damodaran TV, Deshkovskaya AM, et al. 2001. Locomotor and sensorimotor performance deficit in rats following exposure to pyridostigmine bromide, DEET, and peremethin, alone and in combination. Toxicol Sci 60:305–314.

Bai J, Zaj M, Majewski P, K. Pakoa L, Dworanski M, O, Paradowski M. 1994. The effect of chronic exposure to formaldehyde, phenol and organic chlorohydrocarbons on peripheral blood cells and the immune system in humans. *J Investig Allergol* 4:180–183.

Babcock GF, Taylor AF, Hyd BD, Stamkoski RM, Alexander JW. 1987. Flow cytometric analysis of lymphocyte subset phenotypes comparing normal children and adults. *Design Clin Immunol* 5:175–179.

Bigazzi PE, Berek CL, Rosen R. 1986. Antibodies to tissue-specific endocrine, gastrointestinal and neurological antigens. In: *Manual of Clinical Laboratory Immunology* (Rose NB, Friedman H, Fahey JL, eds). Washington, DC:American Society of Microbiology, 762.

Bourke GJ, Daly LE, Mcgiverty J. 1985. Interpretation and Uses of Medical Statistics. Palo Alto, CA:Blackwell Scientific Publications.

Cherry N, Creed F, Silman AJ. 1989. A 15-year surveillance study of antibodies to herpes simplex virus Type 1 and 2 in a cohort of young girls. *J Infect* 19:250–253.

Christenson B, Bottiger M, Svensson A, Jeansson S. 1992. A rapid flow cytometry test for detection of Epstein-Barr virus infection. *J Clin Pathol* 45:298–301.

Cooper GS, Miller FW, Mcgilvray J. 1985. Interpretation and Uses of Medical Statistics. Palo Alto, CA: Blackwell Scientific Publications.

Duffy NW, Flood VL, Anderson J, Banister E, Bondurant M, et al. 1997. Serum paraoxonase (PON1) isozymes: the quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals. *Drug Metab Disp* 25:566–569.

Ferguson E, Cassaday HJ. 2001/2002. Theoretical accounts of 'atypical' BCHE carriers. *Nat Med* 1:1081–1085.

Frankel LB, Jones KH, Abdel-Rahman AA, Damodaran TV, Deshkovskaya AM, et al. 2001. Locomotor and sensorimotor performance deficit in rats following exposure to pyridostigmine bromide, DEET, and peremethin, alone and in combination. Toxicol Sci 60:305–314.

Haley RW, Kurt TL. 1997. Self-reported exposure to neurotoxic chemical combinations in the Gulf War. A cross-sectional epidemiologic study. JAMA 277:228–245.

Kang HK, Mahn CM, Lee KY, Murphy FM, Simmons SJ, Young HA, et al. 2002. Evidence for a deployment-related Gulf War syndrome by factor analysis. *Arch Environ Health* 57:61–68.

Kronke K, Koslowe P, Roy M. 1998. Symptoms in 18,495 Persian Gulf veterans. *J Occup Environ Med* 40:520–528.

Kurt TL. 1998. Epidemiological association with Gulf War illness and exposures to anti-cholinesterase. Toxicol Lett 102:103–525.

La Du BN, Billecke S, Hsu R, Haley RW, Broomfield CA. 2001. Serum paraoxonase (PON1) isozymes: the quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals. *Drug Metab Disp* 29:566–569.

Lashof JC, Cassells J. 1998. Illness among Gulf War veterans. *JAMA* 280:1010–1011.

Levine PH, Whiteside TL, Friberg D, Bruant J, Colclough G, Herberman RG. 1998. Dysfunction of natural killer cell activity in a family with chronic fatigue. *Clin Immunol Immunopathol* 88:96–104.

Loewenstein-Lichtenstein Y, Schwarz M, Glick D, Ngaard-Pederesen B, Zakut H, Soreq H. 1995. Genetic predisposition to adverse consequences of anti-cholinesterase in ‘exposed’ BChE carriers. *Nat Med* 1:1081–1085.

Loveless SE, Smith C, Lades GC. 1997. Further evaluation of incorporation of an immunotoxicological assay for assessing humoral immunity for hazard identification purposes in rats on standard toxicology studies. Toxicologist 36:1359.

Luster MI, Munson AE, Thomas PT, Holsapple MP, Penters JD, White KL Jr, et al. 1988. Development of a testing battery to assess chemical-induced immunotoxicity: National Toxicology Program’s guidance for immunotoxicity evaluation in mice. *Fundam Appl Toxicol* 10:2–19.

Luster MI, Porter C, Pait DG, Rosenthal G, Carisal DR, Carisal E, et al. 1993. Risk assessment in immunotoxicology. II. Relationships between immune and host resistance tests. *Fundam Appl Toxicol* 23:71–82.

Maino VC, Suni MA, Ruitenberg JJ. 1995. Rapid flow cytometry method for measuring lymphocyte subset activation. *Cytometry* 20:127–133.

Matheson B, Chisholm SM, Ho-Yen D. 1999. Rapid flow cytometry for measuring lymphocyte subset activation. *Cytometry* 20:127–133.

McConnachie PR, Zahalsky AC. 1991. Immunological consequence of exposure to pentachlorophenol. *Arch Environ Health* 46:249–253.

McConnachie PR, Zahalsky AC. 1992. Immune alterations in humans exposed to the termiticide technical chlordane. *Arch Environ Health* 47:295–301.

Moss JT. 2001. Many Gulf War illnesses may be autoimmune disorders caused by the chemical and biological stressors pyridostigmine bromide, and adrenaline. *Med Hypotheses* 56:155–157.

Patarca R. 2001. Cytokines and chronic fatigue syndrome. *Ann NY Acad Sci* 923:195–200.

Racciatti D, Vecchiet J, Ceccomancini A, Ricci F, Pizzigallo E, 1999. Chronic fatigue syndrome following a toxic exposure. *J Clin Pathol* 46:249–253.

Racciatti D, Vecchiet J, Ceccomancini A, Ricci F, Pizzigallo E. 1999. Chronic fatigue syndrome following a toxic exposure. *J Clin Pathol* 46:249–253.

Ralli SJ, Twyman RE, Gahring LC. 1996. The role of autoimmune mechanisms in Gulf War illness. *J Occup Environ Med* 40:702–708.

Ralli SJ, Twyman RE, Gahring LC. 1996. The role of autoimmune mechanisms in Gulf War illness. *J Occup Environ Med* 40:702–708.
Terryberry JW, Thor G, Peter JE. 1998. Autoantibodies in neurodegenerative diseases: antigen-specific frequencies and intrathelial analysis. Neurobiol Aging 19:205–216.

Thrasher JD, Broughton A, Madison R. 1990. Immune activation and autoantibodies with long-term inhalation exposure to formaldehyde. Arch Environ Health 45:217–233.

Thrasher JD, Heuser G, Broughton A. 2001. Autoimmunity and other immunological abnormalities in humans chronically exposed to chlorpyrifos. Arch Environ Health 57:181–187.

Thrasher JD, Madison R, Broughton A. 1993. Immunologic abnormalities in humans chronically exposed to chlorpyrifos. Arch Environ Health 48:89–93.

Thrasher JD, Vojdani A, Cheung G, Heuser G. 1987. Evidence for formaldehyde antibodies and altered cellular immunity in subjects exposed to formaldehyde in mobile homes. Arch Environ Health 42:347–350.

Urnovitz HB, Tuite JJ, Higashida JM, Murphy WH. 1999. RNAs in the sera of Persian Gulf War veterans have segments homologous to chromosome 22q11.2. Clin Diagn Lab Immunol 6:330–335.

Vojdani A, Campbell AW, Anyanwu E, Kashanian A, Bock K, Vojdani E. 2002. Antibodies to neuro-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A. J Neuroimmunol 129:168–177.

Vojdani A, Campbell A, Brautbar N. 1993. Immune functional abnormalities in patients with silicone breast implants. Toxicol Ind Health 8:415–429.

Vojdani A, Franco AR. 1999. Multiplex PCR for the detection of Mycoplasma fermentans, M. hominis and M. penetrans in patients with chronic fatigue syndrome, fibromyalgia, rheumatoid arthritis, and Gulf War syndrome. J Chronic Fatigue Syndr 5:187–197.

Vojdani A, Ghoneum M, Brautbar N. 1992. Immune alteration associated with exposure to toxic chemicals. Toxicol Ind Health 8:239–254.

Vojdani A, Vojdani E, Cooper E. 2002. Antibodies to myelin basic protein, myelin oligodendrocytes peptides, α-β-crystallin, lymphocyte activation and cytokine production in patients with multiple sclerosis. J Intern Med 254:363–374.

Waters M, Boorman G, Bushel P, Cunningham M, Irwin R, Merrick A, et al. 2003. Systems toxicology and the chemical effects in biological systems (CEBS) knowledge base. Environ Health Perspect 111:811–824.

Whatt RM, Perera FP, Jedrzychowski W, Santella RM, Garte SG, Bell DA. 2000. Association between polycyclic aromatic hydrocarbon-DNA adduct levels in maternal and newborn white blood cells and glutathione-S-transferase and CYPIA1 polymorphism. Cancer Epidem Biomark Prev 9:207–212.

Whiteside TL, Bryant J, Day R, Herbermann RB. 1990. Natural killer cytotoxicity in the diagnosis of immune dysfunction: criteria for a reproducible assay. J Clin Lab Anal 4:102–110.

Whiteside TL, Friberg D. 1998. Natural killer cells and natural killer cell activity in chronic fatigue syndrome. Am J Med 105:275–345.

Willison HJ, Yuki N. 2002. Peripheral neuropathies and anti-glycolipid antibodies. Brain 125:2911–2925.

Wilson SD, McCay JA, Butterworth LF, Munson AE, White KL. 2001. Correlation of suppressed natural killer cell activity with altered host resistance models in B6C3F1 mice. Toxicol Appl Pharmacol 177:208–218.

Winnow CJ, Hemming ML, Allen DM, Guistad GB, Casida JE, Barlow C. 2003. Loss of neuropathy target esterase in mice links organophosphate exposure to hyperactivity. Nat Genet 33:477–485.

Zhang Q, Zhou X-D, Denny T, Ottenweller JE, Lange G, LaManca JJ, et al. 1999. Changes in immune parameters seen in Gulf War Veterans but not in civilians with chronic fatigue. Clin Diag Lab Immunol 6:6–13.